The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy

Current Eye Research

Volumn 38, Issue 7, 2013, Pages 774-780

  Byon, Ik Soo ^a   Jeon, Hye Shin ^a   Kim, Hyun Woong ^b   Lee, Sang Joon ^c   Lee, Ji Eun ^a,d   Oum, Boo Sup ^a,d  

^a Pusan National University Hospital   (South Korea)

^b Pusan Baik Hospital   (South Korea)

^c Kosin University   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

Author keywords

Angiotensin receptor blocker; Proliferative diabetic retinopathy; Renin angiotensin system; Vascular endothelial growth factor; Vitrectomy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; HEMOGLOBIN A1C; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN; VASCULOTROPIN;

ADULT; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE CONTROL; DISEASE DURATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIMIT OF DETECTION; MALE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN BLOOD LEVEL; RETINA MACULA HOLE; TREATMENT DURATION; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RETINAL DETACHMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 84878472930     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.772206     Document Type: Article

References (41)

1. Aiello JP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med 1994;331:1480-1482
2. Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: A systematic review. Br J Ophthalmol 2012;96:167-187
3. Jardeleza MS, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 2009; 24:87-92
4. Abdallah W, Fawzi AA. Anti-VEGF therapy in proliferative diabetic retinopathy. Int Ophthalmol Clin 2009;49: 95-107
5. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930
6. Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000;41:1192-1199
7. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002;86:311-315
8. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, et al. Retinal neovascularization is prevented by blockade of the renin-Angiotensin system. Hypertension 2000;36:1099-1104
9. Fernadez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105: 141-145
10. Nagai N, Oike Y, Noda K, Urano T, Kubota Y, Ozawa Y, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005;46: 2925-2931
11. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, et al. Angiotensin AT(1) and AT(2) receptor differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001;88:22-29
12. Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension. 2004;43:276-281
13. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomized, placebo-controlled trials. Lancet 2008;372:1394-1402
14. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomized placebo-controlled trial. Lancet 2008;372:1385-1393
15. Hernandez C, Burgos R, Canton A, et al. Vitreous level of vascular adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: A case-control study. Diabetes Care 2001;24: 516-521
16. Hernández C, Burgos R, CantÓn A, García-Arumí J, Segura RM, Simó R. Elevated plasma CD105 and vitreous VEGF level in diabetes retinopathy. J Cell Mol Med 2005;9: 692-697
17. Hernández C, Lecube A, Segura RM, Sararols L, Simó R. Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2002;19:655-660
18. Simó R, Lecube A, Segura RM, García Arumí J, Hernández C. Free insulin growth factor-1 and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 2002; 134:376-382
19. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, et al. Vitreous level of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005;139: 476-481
20. Sydorova M, Lee MS. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res 2005;37: 188-190
21. Baharivand N, Zarghami N, Panahi F, Dokht Ghafari MY, Mahdavi Fard A, Mohajeri A. Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clin Ophthalmol 2012;6: 185-191
22. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008-1018
23. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neural ocular tissue of the rat. Eur J Neurosci 1999;11:3387-3394
24. Murata M, Nakagawa M, Takahashi S. Expression and localization of Angiotensin II type 1 receptor mRNA in rat ocular tissues. Ophthalmologica 1997;211:384-386
25. Murata M, Nakagawa M, Takahashi S. Angiotensinogen mRNA is synthesized locally in rat ocular tissues. Ophthalmologica 1997;211:301-304
26. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E. Renin, prorenin, and immunoactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68: 160-167
27. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002;133:537-543
28. Wilkinson-Berka JL, Kelly DJ, Gilbert RE. The interaction between the renin-Angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vasc Res 2001;38:527-610
29. Otani A, Tagaki H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Cir Res 1998;82:619-628
30. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, et al. Angiotensin converting enzyme inhibition ameliorates retinal over expression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-1367
31. Kim HW, Kim JL, Lee HK, Hur DY, Yun IH, Kim SD. Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr Eye Res 2009;34: 976-987
32. Kim JH, Kim JH, Yu YS, Cho CS, Kim KW. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab 2009;29:621-628
33. Nakamura S, Tsuruma K, Shimazawa M, Hara H. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression. Eur J Pharmacol 2012;685:8-14
34. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31
35. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361: 40-51
36. Harindhanavudhi T, Mauer M, Klein R, Zinman B, Sinaiko A, Caramori ML. Renin Angiotensin System Study (RASS) group. Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care 2011;34:1838-1842
37. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003;163: 879-887
38. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002;45: 203-209
39. Cavusoglu AC, Bilgili S, Alaluf A, Doǧan A, Yilmaz F, Aslanca D, et al. Vascular endothelial growth factor in the serum of diabetic patients with retinopathy. Ann Ophthalmol 2007;39:205-208
40. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004;53:550-555
41. Lee JE, Lim DW, Park HJ, Shin JH, Lee SM, Oum BS. Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model. Invest Ophthalmol Vis Sci. 2011;52: 2924-2929